Additional information
by Aimee Donnellan (Author)
The inside story of the creation of Ozempic and its revolutionary impact on public health.
A "cure" for obesity has long been the holy grail for the pharmaceutical industry, one that seemed unattainable until recent breakthroughs in type 2 diabetes research led to the development of Ozempic, a weight loss medication that activates a hormone in the stomach called GLP-1, making people feel fuller for longer. The treatment is so effective that it is already disrupting many industries--from healthcare to fast food to fashion--and it has quickly made its creator, Denmark's Novo Nordisk, the most valuable company in Europe. But the impact of GLP-1s goes far beyond billion-dollar profits; a true long-term cure for obesity could save 40 percent of American adults from dangerous, preventable illnesses. And as more potential benefits emerge, one question looms in the minds of investors, healthcare workers, and politicians: Are these drugs too good to be true?
Author Biography
Aimee Donnellan is a columnist at Reuters, where, since 2017, her reporting has focused on the pharmaceutical, airline, and insurance industries. Previously, she was The Sunday Times's banking correspondent and covered the bond market for the International Financing Review. She holds degrees in English and history from the University of Ireland, Galway, and in journalism from the London School of Journalism. She lives in Galway with her wife and two children. Off the Scales is her first book.
